Reaction

Dyschezia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,978 reports · 85 co-occurring drugs

As of the last recalculation, Dyschezia appears in 2,978 FAERS reports alongside 85 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 24.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Vedolizumab	274	24.4	24.5
Ado-Trastuzumab Emtansine	27	22.6	22.6
Linaclotide	68	18.2	18.3
Infliximab-Dyyb	58	14.1	14.2
Rivastigmine	37	13.9	13.9
Lubiprostone	17	12.6	12.6
Mesalamine	84	10.7	10.7
Polyethylene Glycol 3350	131	10.0	10.0
Teduglutide	19	9.9	9.9
Instalax Polyethylene Glycol 3350	17	9.6	9.6
Midazolam Hydrochloride	36	9.4	9.5
Polyethylene Glycol 400	17	9.4	9.4
Lapatinib	20	9.1	9.1
Rotigotine	18	8.7	8.8
Ropinirole	19	8.7	8.7
Midazolam	30	8.4	8.4
Levodopa	14	8.1	8.1
Ketoprofen	15	8.0	8.0
Pertuzumab	30	7.8	7.8
Patiromer	15	7.6	7.6
Bisacodyl	15	7.5	7.5
Pramipexole	16	7.3	7.3
Regorafenib	12	7.2	7.3
Azathioprine	87	7.1	7.1
Bisacodyl Suppositories	13	7.0	7.1
Biscodyl	13	7.0	7.0
Carbidopa And Levodopa	44	6.6	6.6
Pancrelipase	35	6.4	6.4
Psyllium Husk	9	6.4	6.4
Ribociclib	28	6.2	6.3
Magnesium Hydroxide	12	6.2	6.2
Hyoscyamine Sulfate	8	6.1	6.1
Letrozole Tablets	41	6.0	6.0
Nirmatrelvir And Ritonavir	44	5.8	5.8
Rucaparib	7	5.6	5.6
Dicyclomine Hydrochloride	11	5.4	5.4
Zoledronic Acid	29	5.1	5.1
Letrozole	44	5.1	5.1
Oxazepam	15	4.9	4.9
Brinzolamide	6	4.8	4.8
Loperamide Hydrochloride Oral	7	4.8	4.8
Ruxolitinib	48	4.7	4.7
Capecitabine	60	4.7	4.7
Cannabidiol	15	4.5	4.5
Lanreotide Acetate	5	4.5	4.5
Loperamide Hydrochloride And Dimethicone	20	4.4	4.4
Cladribine	6	4.4	4.4
Haloperidol	15	4.3	4.3
Haloperidol Lactate	15	4.3	4.3
Naltrexone Hydrochloride And Bupropion Hydrochloride	5	4.1	4.1
Olaparib	12	4.0	4.0
Risankizumab-Rzaa	45	3.9	3.9
Niraparib	12	3.8	3.8
Oral Semaglutide	39	3.7	3.7
Upadacitinib	42	3.6	3.6
Sunitinib Malate	20	3.6	3.6
Diroximel Fumarate	6	3.5	3.5
Vibegron	4	3.5	3.5
Ustekinumab	49	3.4	3.4
Rifaximin	10	3.3	3.3
Relugolix	10	3.0	3.0
Nintedanib	13	2.9	2.9
Fentanyl Citrate	7	2.7	2.7
Irinotecan Hydrochloride	5	2.7	2.7
Panitumumab	6	2.7	2.7
Ozanimod Hydrochloride	3	2.5	2.5
Abemaciclib	7	2.5	2.5
Tolvaptan	5	2.4	2.4
Apalutamide	4	2.4	2.4
Gefitinib	3	2.3	2.3
Avapritinib	4	2.3	2.3
Clozapine	41	2.3	2.3
Elexacaftor, Tezacaftor, And Ivacaftor	4	2.2	2.2
Venetoclax	19	2.2	2.2
Pazopanib Hydrochloride	8	2.1	2.1
Cabozantinib	13	1.9	1.9
Axitinib	5	1.8	1.8
Tafamidis	3	1.8	1.8
Erenumab-Aooe	14	1.8	1.8
Osimertinib	7	1.5	1.5
Vigabatrin	3	1.4	1.4
Copper	8	1.3	1.3
Abaloparatide	5	1.2	1.2
Tirzepatide	26	1.1	1.1
Voxelotor	3	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.